Business
Marvel Biosciences' Lead Drug Candidate MB-204 Demonstrates a 400% Increase in the Survival Rate of Animals Treated with a High Dose of the Cancer Treatment Cis-Platinum
Calgary, Alberta--(Newsfile Corp. - November 22, 2022) - Marvel Biosciences Corp. (TSXV: MRVL...
About this update from Marvel Biosciences Corp
[{"type":"text","content":"Marvel Biosciences' Lead Drug Candidate MB-204 Demonstrates a 400% Increase in the Survival Rate of Animals Treated with a High Dose of the Cancer Treatment Cis-PlatinumCalgary, Alberta--(Newsfile Corp. - November 22, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the \"Company\" or \"Marvel\"), is pleased to announce that in a recent study done by the Company, its lead drug candidate MB-204 demonstrated a 400% increase in the survival rate of animals being treated by high doses of chemotherapy treatment, cis-platinum.\"We are seeing great momentum being built around our lead drug candidate MB-204, which, as previously reported, has shown significant potential to help patients suffering from Alzheimer's and depression,\" said Rod Matheson, CEO of Marvel Biosciences. \"This recent study supports a significant increase in our market opportunity to also help cancer patients improve their quality of life and reduce organ damage that results from the very effective but highly toxic chemotherapy treatment, cis-platinum.\" Cis-platinum is commonly used for a wide range of cancers and is the most powerful chemotherapeutic treatment available today. Unfortunately, it has multiple potentially-catastrophic side effects including kidney and nerve damage, cognitive dysfunction and hearing loss. The risk of nephrotoxicity in patients taking cis-platinum is between 20% and 35% and leads to death, in the case of acute kidney injury (AKI) patients, forcing clinicians to carefully dose and monitor kidney health.1 In some cases cis-platinum treatment for cancer has to be terminated early without achieving the desired outcome. David Blum, a key member of Marvel's scientific advisory board, recently published data showing inhibiting the adenosine A2a receptor, using the approved drug Istradefylline, reduces kidney and nerve damage in cis-platinum treated animals.2 It was also previously reported that inhibiting the A2a receptor prevented cognitive dysfunction as well.3 Marvel's MB-204 directly targets the A2a receptor and blocks its activity. \"When we treated animals with MB-204, our fluorinated derivative of Istradefylline , we saw a significant increase in their survival rate from between 20% and 80% while they were being given a high-dose course of cis-platinum,\" said Dr. M...